Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
38.67
+0.10 (0.26%)
Jul 11, 2025, 11:40 AM - Market open
Apogee Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Apogee Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $97.5, which forecasts a 152.13% increase in the stock price over the next year. The lowest target is $89 and the highest is $116.
Price Target: $97.5 (+152.13%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Apogee Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $116 | Strong Buy | Reiterates | $116 | +199.97% | Jul 2, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $95 | Strong Buy | Initiates | $95 | +145.67% | Mar 13, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 10, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 12, 2024 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $95 → $110 | Strong Buy | Reiterates | $95 → $110 | +184.46% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
27.95M
Revenue Next Year
235.64M
from 27.95M
Increased by 743.14%
EPS This Year
-4.45
from -3.30
EPS Next Year
-5.61
from -4.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.69 | -4.20 | -4.35 | ||
| Avg | -4.45 | -5.61 | -6.30 | ||
| Low | -5.85 | -11.07 | -11.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.